PMID- 28894200
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20190613
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Sep 11
TI  - Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency.
PG  - 11137
LID - 10.1038/s41598-017-11605-2 [doi]
LID - 11137
AB  - Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor 
      involved in DNA replication in lower species, which is strongly expressed in 
      normal stem cell populations and progenitor cell populations. Recently, we have 
      investigated PSF1 functions in cancer cells and found that PSF1 plays a 
      significant role in tumour growth. These findings provide initial evidence for 
      the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains 
      an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 
      peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass 
      spectrometry and identified PSF1(79-87) peptide (YLYDRLLRI) that has the highest 
      prediction score using an in silico algorithm. PSF1(79-87) peptide induced 
      PSF1-specific cytotoxic T lymphocyte responses such as the production of 
      interferon-gamma and cytotoxicity. Because PSF1 is expressed in cancer cell 
      populations and highly expressed in cancer stem cell populations, these data 
      suggest that vaccination with PSF1(79-87) peptide may be a novel therapeutic 
      strategy for cancer treatment.
FAU - Yoshida, Mari
AU  - Yoshida M
AD  - Biomarker R&D Department, Shionogi & Co., Ltd, Osaka, 561-0825, Japan.
AD  - Department of Signal Transduction, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Osaka, 561-0825, Japan.
FAU - Ishioka, Yukichi
AU  - Ishioka Y
AD  - Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, 
      561-0825, Japan.
FAU - Ozawa, Takamasa
AU  - Ozawa T
AD  - Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, 
      561-0825, Japan.
FAU - Okuyama, Hirohisa
AU  - Okuyama H
AD  - Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, 
      561-0825, Japan.
FAU - Iguchi, Motofumi
AU  - Iguchi M
AD  - Medical Affairs Department, Shionogi & Co., Ltd, Osaka, 530-0012, Japan.
FAU - Ota, Takeshi
AU  - Ota T
AD  - Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, 
      561-0825, Japan.
FAU - Ito, Takaomi
AU  - Ito T
AD  - Shionogi TechnoAdvance Research Co., Ltd, Osaka, 561-0825, Japan.
FAU - Nagira, Morio
AU  - Nagira M
AD  - Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, 
      561-0825, Japan.
FAU - Morita, Atsushi
AU  - Morita A
AD  - Biomarker R&D Department, Shionogi & Co., Ltd, Osaka, 561-0825, Japan.
FAU - Tanaka, Hidekazu
AU  - Tanaka H
AD  - Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, 
      561-0825, Japan.
FAU - Naito, Hisamichi
AU  - Naito H
AD  - Department of Signal Transduction, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Osaka, 561-0825, Japan.
FAU - Kidoya, Hiroyasu
AU  - Kidoya H
AD  - Department of Signal Transduction, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Osaka, 561-0825, Japan.
FAU - Takakura, Nobuyuki
AU  - Takakura N
AD  - Department of Signal Transduction, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Osaka, 561-0825, Japan. 
      ntakaku@biken.osaka-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20170911
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 2)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
RN  - 0 (TAP1 protein, human)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 2/chemistry/*immunology
MH  - Animals
MH  - Antigen Presentation
MH  - Cancer Vaccines/*immunology
MH  - Cell Line, Tumor
MH  - Chromatography, Liquid
MH  - Cytotoxicity, Immunologic
MH  - Disease Models, Animal
MH  - Epitopes, T-Lymphocyte/chemistry/immunology
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunogenicity, Vaccine
MH  - Mice
MH  - Neoplasms/immunology
MH  - Peptides/blood/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology/metabolism
MH  - Tandem Mass Spectrometry
PMC - PMC5593935
COIS- The authors declare that they have no competing interests.
EDAT- 2017/09/13 06:00
MHDA- 2019/06/14 06:00
PMCR- 2017/09/11
CRDT- 2017/09/13 06:00
PHST- 2017/05/19 00:00 [received]
PHST- 2017/08/25 00:00 [accepted]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2017/09/11 00:00 [pmc-release]
AID - 10.1038/s41598-017-11605-2 [pii]
AID - 11605 [pii]
AID - 10.1038/s41598-017-11605-2 [doi]
PST - epublish
SO  - Sci Rep. 2017 Sep 11;7(1):11137. doi: 10.1038/s41598-017-11605-2.